Company Description
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases.
The company’s lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gerald Proehl |
Contact Details
Address: 3525 Del Mar Heights Road, Suite 332 San Diego, California 92130 United States | |
| Phone | 858 800 2543 |
| Website | dermatarx.com |
Stock Details
| Ticker Symbol | DRMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001853816 |
| CUSIP Number | 249845108 |
| ISIN Number | US2498453065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer and Chairman |
| David F. Hale | Co-Founder and Lead Independent Director |
| Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President and Chief Financial Officer |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President and Chief Development Officer |
| Sean Proehl | Senior Director of Legal and Business Development |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Sep 27, 2024 | D | Notice of Exempt Offering of Securities |
| Sep 24, 2024 | EFFECT | Notice of Effectiveness |
| Sep 24, 2024 | 424B3 | Prospectus |
| Sep 23, 2024 | UPLOAD | Filing |
| Sep 19, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 17, 2024 | 8-K | Current Report |
| Aug 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |